|1.||Sato, Koh: 3 articles (11/2005 - 09/2003)|
|2.||Yamada-Okabe, Hisafumi: 2 articles (11/2005 - 09/2004)|
|3.||Ogata, Etsuro: 2 articles (11/2005 - 09/2004)|
|4.||Tsunenari, Toshiaki: 2 articles (11/2005 - 09/2004)|
|5.||Saito, Hidemi: 2 articles (11/2005 - 09/2004)|
|6.||Onuma, Etsuro: 2 articles (11/2005 - 09/2004)|
|7.||Esbrit, P: 2 articles (07/2000 - 06/2000)|
|8.||Richter, Wiltrud: 1 article (10/2014)|
|9.||Grossner, Tobias: 1 article (10/2014)|
|10.||Dexheimer, Verena: 1 article (10/2014)|
|1.||Body Weight (Weight, Body)
01/01/1994 - "Four groups of 7-8-month-old rats were treated sc daily for 13 d with PTHrP (1-34) or (107-111) at the dose of 1 or 3 nmol/100 g body weight. "
09/01/2013 - "We found that subcutaneous injection of PTHrP(1-34) (40 or 80 μg/kg body weight every day) in OVX rats increased lumbar and femoral BMD, improved bone biomechanical properties, enhanced bone strength, and promoted bone formation. "
09/01/2013 - "We used an ovariectomized (OVX) rat model of osteoporosis to study the effects of PTHrP(1-34) on bone metabolism by measuring bone mineral density (BMD), bone histomorphometrics, and biomechanical parameters. "
01/01/2014 - "Recombinant human parathyroid hormone related protein 1-34 and 1-84 and their roles in osteoporosis treatment."
09/01/2013 - "Based on our results, intermittent low-dose PTHrP(1-34) injection promoted bone formation in OVX rats, suggesting a high potential for therapeutic use in osteoporosis patients."
09/01/2013 - "Effects of different dosages of parathyroid hormone-related protein 1-34 on the bone metabolism of the ovariectomized rat model of osteoporosis."
04/01/1995 - "The role of PTHrP during aging (especially in post-menopausal women in which bone loss may induce osteoporosis) remains unknown and might be of peculiar interest since PTHrP (1-34) and (107-111) are able to restore bone loss induced by ovariectomy in rats."
09/15/2001 - "Although PTHrP expression has been reported to be associated with more aggressive malignancies, the data from the current study suggest that PTHrP 1-34 was a paracrine growth inhibitor in BEN human lung carcinoma cells. "
03/01/1990 - "The serum level of PTHrP was examined using human PTHrP (1-34) RIA in lung carcinomas. "
01/01/1997 - "It has been previously reported that 8701-BC cells, derived from a primary carcinoma of the breast, constitutively express parathyroid hormone (PTH)-related peptide (PTHrP) and PTH/PTHrP receptor (PTH/PTHrP-R) genes, that N-terminal, mid-regional and C-terminal immunoreactive PTHrP can be found in cell conditioned medium and, furthermore, that exogenously added PTHrP (1-34), (67-86) and, to a minor extent, (107-139) are anti-mitogenic but promote Matrigel invasion by this cell line. "
|4.||Pituitary Neoplasms (Pituitary Adenoma)
|5.||Chronic Kidney Failure (Chronic Renal Failure)
|1.||Parathyroid Hormone-Related Protein
|2.||Immune Sera (Antisera)
|3.||Parathyroid Hormone (Parathormone)
|4.||Adenylate Cyclase (Adenylyl Cyclase)
|5.||bovine parathyroid hormone (1-34)
|7.||Conditioned Culture Media
|10.||tartrate-resistant acid phosphatase (TSAP)